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Pain, particularly chronic pain, is still an unsolved medical condition. Central goals in
pain control are to provide analgesia of adequate efficacy and to reduce complications
associated with the currently available drugs. Opioids are the mainstay for the treatment
of moderate to severe pain. However, opioid pain medications also cause detrimental
side effects, thus highlighting the need of innovative and safer analgesics. Opioids
mediate their actions via the activation of opioid receptors, with the mu-opioid receptor
as the primary target for analgesia, but also for side effects. One long-standing focus
of drug discovery is the pursuit for new opioids exhibiting a favorable dissociation
between analgesia and adverse effects. In this study, we describe the in vitro and in vivo
pharmacological profiles of the 14-O-phenylpropyl substituted analog of the mu-opioid
agonist 14-O-methyloxymorphone (14-OMO). The consequence of the substitution of
the 14-O-methyl in 14-OMO with a 14-O-phenylpropyl group on in vitro binding and
functional activity, and in vivo behavioral properties (nociception and gastrointestinal
motility) was investigated. In binding studies, 14-O-phenylpropyloxymorphone (POMO)
displayed very high affinity at mu-, delta-, and kappa-opioid receptors (K i values in
nM, mu:delta:kappa = 0.073:0.13:0.30) in rodent brain membranes, with complete
loss of mu-receptor selectivity compared to 14-OMO. In guinea-pig ileum and mouse
vas deferens bioassays, POMO was a highly efficacious and full agonist, being more
potent than 14-OMO. In the [35S]GTPγS binding assays with membranes from CHO
cells expressing human opioid receptors, POMO was a potent mu/delta-receptor full
agonist and a kappa-receptor partial agonist. In vivo, POMO was highly effective
in acute thermal nociception (hot-plate test, AD50 = 0.7 nmol/kg) in mice after
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subcutaneous administration, with over 70- and 9000-fold increased potency than 14-
OMO and morphine, respectively. POMO-induced antinociception is mediated through
the activation of the mu-opioid receptor, and it does not involve delta- and kappa-
opioid receptors. In the charcoal test, POMO produced fourfold less inhibition of the
gastrointestinal transit than 14-OMO and morphine. In summary, POMO emerges as
a new potent mixed mu/delta/kappa-opioid receptor agonist with reduced liability to
cause constipation at antinociceptive doses.
Keywords: pain, analgesia, constipation, opioid agonist, opioid receptor, morphinans, binding affinity
INTRODUCTION
Pain, particularly chronic pain, remains an ongoing global health
and socioeconomical problem (Severino et al., 2018), affecting
more people than cancer, heart disease, and diabetes combined
(Skolnick and Volkow, 2016). Furthermore, comorbidity of
chronic pain with mood disorders (e.g., depression, anxiety)
in pain patients is well-recognized (Nicholson and Verma,
2004; Tsang et al., 2008; Miller and Cano, 2009). Opioids
are the most effective drugs for the treatment of moderate
to severe pain (Pasternak, 2014; Stein, 2016). However, their
wide use is hampered by unwanted side effects, including
constipation, apnea, sedation, nausea, tolerance, and dependence
(Benyamin et al., 2008; Imam et al., 2018). A huge increase
in medical use and abuse of prescription opioids with raised
opioid-related morbidity and mortality has been reported
in the past years (Skolnick and Volkow, 2016; Severino
et al., 2018). Ongoing monitoring of pain patients receiving
opioids to ensure appropriate use and effectiveness is of
major importance. The central goal is to balance the patient’s
pain relief, potential harmful consequences of opioids, and
quality of life. Opioids induce their actions via the activation
of opioid receptors, that is, mu (MOR), delta (DOR), and
kappa (KOR), as members of the large family of G protein-
coupled receptors (GPCRs) with seven transmembrane domains
(Kieffer and Evans, 2009; Shang and Filizola, 2015). Opioid
receptors modulate neurotransmission in neuronal circuits
that subserve pain both at central and peripheral sites (Stein
and Machelska, 2011). One long-standing focus of opioid
drug discovery is the pursuit for safe and effective analgesics
with more favorable pharmacological features. Different
approaches are therefore being evaluated to mitigate the
deleterious effects of opioid analgesics, with extended reports
into the field over the past years (Stein and Machelska,
2011; Aldrich and McLaughlin, 2012; Albert-Vartanian
et al., 2016; Del Vecchio et al., 2017; Günther et al., 2017;
Madariaga-Mazón et al., 2017; Schmid et al., 2017; Yekkirala
et al., 2017; Livingston and Traynor, 2018; Pergolizzi et al.,
2018).
The MOR is the primary target for analgesia, but also
for side effects of opioid analgesics (Pasternak and Pan,
2013). The present understanding of the MOR function is
persistently increasing with the crystal (active and inactive)
structures of the MOR available (Filizola, 2018). Among clinically
used opioids, morphinans including morphine, oxycodone, and
oxymorphone, are of key importance as potent MOR agonists
(Fürst and Hosztafi, 2008; Spetea et al., 2013). Modifications
at position 14 of the morphinan skeleton were targeted by
us and others with the prospect of designing novel MOR
analgesics, which retain their opioid analgesic properties, but
with fewer or no adverse effects (Fürst and Hosztafi, 2008;
Lewis and Husbands, 2011; Spetea and Schmidhammer, 2012;
Spetea et al., 2013). We have reported that the introduction
of a 14-methoxy group in oxymorphone leading to 14-O-
methyloxymorphone (14-OMO, Figure 1) (Schmidhammer
et al., 1984) not only increased binding affinity and agonist
potency at the MOR, but also resulted in a significant increase
in antinociceptive potency in various pain models in rodents
(Schmidhammer et al., 1984; Lattanzi et al., 2005; Spetea
et al., 2010; Dumitrascuta et al., 2017). However, 14-OMO
induces the typical opioid-like side effects (Schmidhammer
et al., 1984; Lattanzi et al., 2005). In this study, we describe
the in vitro and in vivo pharmacological profiles of the 14-
O-phenylpropyl substituted analog of 14-OMO, namely 14-O-
phenylpropyloxymorphone (POMO, Figure 1), which emerges
as a new potent mixed mu/delta/kappa-opioid receptor agonist




Cell culture media and supplements were obtained from
Sigma-Aldrich Chemicals (St. Louis, MO, United States) or
Life Technologies (Carlsbad, CA, United States). Radioligands,
[3H][D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin ([3H]DAMGO),
[3H]5α,7α,8β-(-)N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)
dec-8-yl]benzeneacetamide ([3H]U69,593), and guanosine 5′-O-
(3-[35S]thio)-triphosphate ([35S]GTPγS), were purchased from
PerkinElmer (Boston, MA, United States). [3H][Ile5,6]deltorphin
II was obtained from the Institute of Isotopes Co. Ltd. (Budapest,
Hungary). Guanosine diphosphate (GPD), GTPγS and opioid
ligands, naloxone, DAMGO, [D-Pen2,D-Pen5]enkephalin
(DPDPE), U69,593 and naltrindole, were obtained from
Sigma-Aldrich Chemicals (St. Louis, MO, United States).
Nor-binaltorphimine (nor-BNI) was purchased from Tocris
(Abingdon, United Kingdom). Morphine hydrocloride was
obtained from S.A.L.A.R.S. (Como, Italy). Dermorphin and
deltorphin I were synthesized as previously described (Erspamer
et al., 1989; Negri et al., 1992). 14-OMO and POMO were
prepared as described earlier (Schmidhammer et al., 1984; Spetea
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FIGURE 1 | Structures of 14-O-methyloxymorphone (14-OMO) and
14-O-phenylpropyloxymorphone (POMO).
et al., 2004). All other chemicals were of analytical grade and
obtained from standard commercial sources.
Animals
Male CD-1 mice (20–25 g) and guinea-pigs (400–500 g)
were obtained from Charles River (Lecco, Italy, or Sulzfeld,
Germany). Animals were housed at 22◦C with food and water
ad libitum and a 12-h light/dark cycle. Animals were used
after 4–5 days of acclimatization to the housing conditions.
All animal studies were conducted in accordance with ethical
guidelines and animal welfare standards according to Italian and
Austrian regulations for animal research and were approved by
the Animal Care and Use Committee of the Italian Ministry
of Health and the Austrian Federal Ministry of Science and
Research. All efforts were made to minimize animal suffering
and to reduce the number of animals used. For behavioral
studies, compounds were dissolved in sterile saline solution,
and administered subcutaneously (s.c.) to mice. Separate
groups of mice received the respective dose of compound,
and individual mice were only used once for behavioral
testing.
Radioligand Binding Assays
Membranes were prepared from Sprague–Dawley rat brains or
guinea-pig brains obtained frozen from Labortierkunde und
Laborgenetik, Medizinische Universität Wien, Himberg, Austria
according to the described procedure (Lattanzi et al., 2005).
Protein content of brain homogenates was determined by
the method of Bradford using bovine serum albumin as the
standard (Bradford, 1976). Binding experiments were performed
in 50 mM Tris-HCl buffer (pH 7.4.) in a final volume of
1 ml containing 0.3–0.5 mg protein and various concentrations
of test compound as described previously (Lattanzi et al.,
2005). Rat brain membranes were incubated either with
[3H]DAMGO (1 nM, 45 min, 35◦C) or [3H][Ile5,6]deltorphin
II (0.5 nM, 45 min, 35◦C) for labeling MOR and DOR,
respectively. Guinea-pig brain membranes were incubated with
[3H]U69,593 (1 nM, 30 min, 30◦C) for labeling the KOR.
Nonspecific binding was determined using 10 µM naloxone.
After incubation, reactions were terminated by rapid filtration
through Whatman glass fiber filters. Filters were washed three
times with 5 ml of ice-cold 50 mM Tris-HCl buffer (pH
7.4) using a Brandel M24R cell harvester (Gaithersburg, MD,
United States). Radioactivity retained on the filters was counted
by liquid scintillation counting using a Beckman Coulter LS6500
(Beckman Coulter Inc., Fullerton, CA, United States). All
experiments were performed in duplicate and repeated at least
three times.
[35S]GTPγS Binding Assays
Chinese hamster ovary (CHO) cells stably expressing the
human opioid receptors, MOR, DOR, or KOR (CHO-hMOR,
CHO-hDOR, and CHO-hKOR cell lines) were kindly provided
by Dr. Lawrence Toll (SRI International, Menlo Park, CA,
United States). The CHO-hMOR and CHO-hDOR cell lines
were maintained in Dulbecco’s Minimal Essential Medium
(DMEM)/Ham’s F-12 medium supplemented with fetal bovine
serum (FBS, 10%), penicillin/streptomycin (0.1%), L-glutamine
(2 mM), and geneticin (400 µg/ml). The CHO-hKOR cell
line was maintained in DMEM supplemented with FBS
(10%), penicillin/streptomycin (0.1%), L-glutamine (2 mM),
and geneticin (400 µg/ml). Cell cultures were maintained at
37◦C in 5% CO2 humidified air. Binding of [35S]GTPγS to
membranes from CHO cells stably expressing the human opioid
receptors was conducted according to the published procedure
(Ben Haddou et al., 2014). Cell membranes were prepared
in Buffer A (20 mM HEPES, 10 mM MgCl2, and 100 mM
NaCl, pH 7.4) as described (Ben Haddou et al., 2014). Cell
membranes (5–10 µg) in Buffer A were incubated with 0.05 nM
[35S]GTPγS, 10 µM GDP, and various concentrations of test
compound in a final volume of 1 ml, for 60 min at 25◦C.
Nonspecific binding was determined using 10 µM GTPγS,
and the basal binding was determined in the absence of test
compound. Samples are filtered over Whatman glass GF/B
fiber filters and counted as described for binding assays. All
experiments were performed in duplicate and repeated at least
three times.
Bioassays
Preparations of the myenteric plexus-longitudinal muscle
obtained from the small intestine of male guinea-pigs (GPI)
and preparations of vasa deferentia of mouse (MVD) were
used for field stimulation with bipolar rectangular pulses of
supramaximal voltage as described earlier (Lattanzi et al., 2005).
Test compounds were evaluated for their ability to inhibit the
electrically evoked twitch, and agonist potency was compared
with that of the MOR agonist, dermorphin, in GPI, and with
the DOR agonist deltorphin I, in MVD. Concentration-response
effects were established. All experiments were repeated at least
three times.
Antinociception
Antinociception was assessed using the hot-plate assay
performed as described (Lattanzi et al., 2005). Hot-plate
latencies were determined by placing each mouse on a hot-
plate kept at 55 ± 1◦C and observing the occurrence of a
nociceptive response (licking of a paw or jumping). Each animal
served as its own control. Before drug s.c. administration,
each animal was tested, and the basal latency to thermal
stimulation was recorded. Animals not responding within
3 s were not used. In order to avoid possible tissue damage,
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a cut-off time of 12 s was applied. Mice were tested for
antinociception after drug administration, and time- and
dose-response effect was established. For the antagonism
studies, naloxone (1 mg/kg) or naltrindole (3 mg/kg) were
s.c. administered 10 min before POMO (2 nmol/kg, s.c.).
Nor-BNI (20 mg/kg, s.c.) was administered 24 h before
POMO. Antinociception was assessed 20 min after POMO s.c.
injection using the hot-plate assay. Doses and pretreatment
times of the antagonists were chosen based on pilot studies
and previous research (Lattanzi et al., 2002; Erli et al.,
2017). Antinociceptive response was expressed as maximum
possible effect (%MPE), calculated according to the equation:
%MPE = (test latency − basal latency)/(cut-off − basal
latency) × 100. Each experimental group included six to eight
animals.
Gastrointestinal Transit
The charcoal meal test was used to measure gastrointestinal
transit (Broccardo et al., 1998). Mice were fasted for 18 h,
with free access to water for the entire study. Animals
received 0.25 ml of a suspension of charcoal consisting of
10% (w/v) charcoal suspension in a 5% gum Arabic solution,
administered by a gastric tube. Groups of mice were s.c.
administered different doses of test drug (morphine: 3900,
6690, and 8000 nmol/kg; 14-OMO: 32, 53, and 90 nmol/kg;
POMO: 0.35, 0.70, and 1.6 nmol/kg) or vehicle (saline),
15 min before the charcoal meal, and were sacrificed 15 min
later. The stomach and small intestine were separated from
the omentum to avoid stretching. The length of the intestine
from the pyloric sphincter to the ileocecal junction and the
distance traveled by the charcoal meal were measured. The
distance traveled by the charcoal meal was expressed as percent
of the total length of the small intestine, and the effect was
computed as follows: %inhibitory effect = 100 − [(%length
traveled after test compound)/(%length traveled after
vehicle) × 100]. Each experimental group included eight
animals.
Statistical Analysis
Data were analyzed and graphically processed using the
GraphPad Prism 5.0 Software (GraphPad Prism Software
Inc., San Diego, CA) and are presented as means ± SEM.
For in vitro assays, inhibitor constant (K i in nM), potency
(EC50 or IC50 in nM), and efficacy (% stimulation) values were
determined from concentration-response curves by nonlinear
regression analysis. The K i values were determined by the
method of Cheng and Prusoff (1973). In the [35S]GTPγS
binding assays, efficacy was determined relative to the
reference full opioid agonists, DAMGO (MOR), DPDPE
(DOR), and U69,593 (KOR). The AD50 defined as the dose
that produced an antinociceptive effect equal to 50% MPE
in the hot-plate test, the ED50 defined as the dose that
produced 50% inhibitory effect in the charcol test, and 95%
confidence intervals (95% CI) were calculated from dose-
response curves (Tallarida and Murray, 1986). Data were
statistically evaluated using one-way ANOVA with Tukey’s
post hoc test for multiple comparisons and unpaired t-test
for comparisons between two groups, with significance set at
P < 0.05.
RESULTS
In vitro Pharmacology – Opioid Receptor
Binding and Functional Activity
Binding affinity and functional in vitro activity of POMO were
evaluated at MOR, DOR, and KOR and compared to the
profile of 14-OMO. For comparison purposes, the affinity and
potency/efficacy data of morphine (Ben Haddou et al., 2014) are
also presented. Affinities at opioid receptors were determined in
competition binding assays using rat brain (MOR and DOR) and
guinea-pig brain (KOR) membrane preparations (Lattanzi et al.,
2005). As shown in Figure 2A, POMO effectively inhibited in a
concentration-dependent manner the binding of selective opioid
radioligands to brain membranes. Based on the calculated K i
values, POMO displayed very high affinity in the picomolar range
at the MOR (K i = 0.073 nM), similar to the parent compound
14-OMO (P > 0.05, t-test). However, POMO had also low K i
values in the subnanomolar range at DOR and KOR, that were
significantly lower than the K i values of 14-OMO (P < 0.05,
t-test), thus indicating a complete loss of MOR selectivity of
POMO when compared to 14-OMO, as well as to morphine
(Table 1).
The opioid agonist in vitro activities of POMO were initially
assessed on smooth muscle preparations, the GPI and MVD,
as well-known widely used bioassays (Leslie, 1987). The GPI
is primarily a MOR preparation, even though the ileum also
contains KOR. In the MVD, the opioid effects are mostly
mediated through the DOR, but MOR and KOR also exist in
the tissue. Dermorphin and deltorphin I were used as reference
MOR and DOR agonists, respectively. POMO was effective in
inhibiting the electrically stimulated twitch in GPI and MVD
preparations, with IC50 values listed in Table 2. In the GPI
assay, POMO exhibited potent and full agonist activity at the
MOR (IC50 = 1.2 nM), with a slight albeit significant increase
(P< 0.05, t-test) than that of 14-OMO. In the MVD preparation,
POMO was 1000-fold more potent than 14-OMO as agonist
(P < 0.05, t-test), in line with its enhanced binding affinities
at DOR and KOR when compared to 14-OMO. Compared to
morphine, POMO was over 250- and 50,000-fold more potent as
agonist in the GPI and MVD, respectively (Table 2).
In addition to functional bioassays, we assessed the effect
of POMO on G protein activation using the ligand-stimulated
[35S]GTPγS binding assay with membranes from CHO cells
stably expressing the human opioid receptors (Ben Haddou
et al., 2014). As shown in Figure 2B, POMO produced a
concentration-dependent increase in the [35S]GTPγS binding.
Agonist potencies (ED50) and efficacies (% stimulation) values
are listed in Table 2. Stimulation of [35S]GTPγS binding was
determined and compared to the effect of prototypical full
agonists, DAMGO (MOR), DPDPE (DOR), and U69,593 (KOR).
POMO was a highly potent agonist at all three receptors, with
full efficacy at MOR and DOR, and partial agonism at the
KOR (Figure 2B and Table 2). The in vitro functional activity
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FIGURE 2 | In vitro binding and agonist profile of POMO at the opioid receptors. (A) Concentration-dependent inhibition by POMO and 14-OMO of [3H]DAMGO
(MOR) and [3H][Ile5,6]deltorphin II (DOR) binding using rat brain membranes, and by [3H]U69,593 (KOR) using guinea-pig brain membranes, determined in
competition binding assays. (B) Concentration-dependent stimulation of [35S]GTPγS binding by POMO and 14-OMO determined in the [35S]GTPγS binding assays
using membranes from CHO cells expressing human opioid receptors. Percentage stimulation is presented relative to the maximum simulation of reference agonists
DAMGO (MOR), DPDPE (DOR), and U69,593 (KOR). Values are expressed as the mean ± SEM (n ≥ 3).
was also affected by the substitution of the 14-O-methyl group
with a 14-O-phenylpropyl group, as POMO showed a significant
increase in potency than 14-OMO as defined by the higher
EC50 values (20-fold at MOR, 151-fold at DOR, and 411-fold
at KOR) (P < 0.05, t-test), while retaining the full agonism
at MOR/DOR and partial agonism at the KOR (Table 2).
Subsequently, the functional MOR selectivity was significantly
decreased for POMO.
In vivo Pharmacology – Antinociceptive
Activity and Gastrointestinal Transit in
Mice
POMO was evaluated for antinociceptive activity in a mouse
model of acute thermal nociception, the hot-plate assay
(Lattanzi et al., 2005). Subcutaneous administration of POMO
produced time- and dose-dependent increase in latencies to
thermal stimulus, with the peak of antinociceptive response
occurring at 20 min (Figure 3). Antinociceptive potency as
AD50 value (and 95% CI) was calculated at the peak of
action and compared to 14-OMO and morphine. As shown
in Table 3, the in vivo functional activity was affected by
the replacement of the 14-O-methyl group with a 14-O-
phenylpropyl substituent, affording an opioid agonist with more
than 70-fold increased antinociceptive potency than 14-OMO.
Compared to morphine, POMO was over 9000-fold more
effective in producing antinociception in the hot-plate assay in
mice.
To determine the relative involvement of the opioid
receptor agonist activity in eliciting POMO-induced
antinociception, mice were s.c. pretreated with the MOR
antagonist naloxone (1 mg/kg), DOR antagonist naltrindole
TABLE 1 | Binding affinities and selectivity of POMO at the opioid receptors.
Affinity, Ki (nM) Selectivity
MOR DOR KOR DOR/MOR KOR/MOR
14-OMOa 0.10 ± 0.01 4.80 ± 0.22 10.2 ± 2.0 48 102
POMO 0.073 ± 0.007 0.13 ± 0.02∗∗∗ 0.30 ± 0.01∗∗ 1.8 4.1
Morphinea 6.55 ± 0.74 217 ± 19 113 ± 9 33 17
Competition binding assays were performed with membranes from rat brain (MOR and DOR) or guinea-pig brain (KOR). aData from Lattanzi et al. (2005). Values are
means ± SEM of at least three experiments. ∗∗P < 0.01 and ∗∗∗P < 0.001 vs. 14-OMO (unpaired t-test).
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TABLE 2 | In vitro functional activity of POMO at the opioid receptors.
Bioassaya [35S]GTPγS Bindingb
IC50 (nM) MOR DOR KOR
GPI MVD EC50 (nM) % stim. EC50 (nM) % stim. EC50 (nM) % stim.
14-OMO 2.0 ± 0.3c 30.5 ± 5.5c 1.62 ± 0.48 97 ± 6 43.8 ± 11.7 106 ± 1 144 ± 32 65 ± 7
POMO 1.2 ± 0.21∗ 0.03 ± 0.0013∗∗∗ 0.082 ± 0.017∗∗ 100 ± 8 0.28 ± 0.14∗∗ 91 ± 8 0.38 ± 0.13∗∗ 39 ± 5
Morphine 311 ± 29c 1600 ± 121c 34.4 ± 5.1d 89 ± 17d 668 ± 65d 109 ± 14d 710 ± 23d 76 ± 2d
Dermorphin 1.3 ± 0.27 18 ± 0.31
Deltorphin I 1239 ± 132 0.19 ± 0.03
DAMGO 14.7 ± 1.9 100
DPDPE 1.26 ± 0.76 100
U69,593 16.7 ± 3.0 100
aFunctional bioactivity was determined using GPI and MVD preparations. b[35S]GTPγS binding assays were performed with membranes from CHO stably expressing
human opioid receptors. Percentage stimulation (% stim.) is presented relative to the reference full agonists DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR). cData from
Lattanzi et al. (2005). dData from Ben Haddou et al. (2014). Values are means ± SEM of at least three experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, vs. 14-OMO
(unpaired t-test).
FIGURE 3 | Acute thermal antinociception induced by POMO in the hot-plate assay in mice after s.c. administration. (A) Time-dependent antinociceptive effects of
POMO. (B) Comparison of dose-dependent antinociceptive effects of POMO, 14-OMO, and morphine. Data are shown as mean %MPE ± SEM (n = 6–8 mice per
group).
(3 mg/kg), or KOR antagonist nor-BNI (20 mg/kg) prior
to POMO s.c. injection, and tested in the hot-plate
assay (Figure 4). Antinociception induced by the s.c.
administration of 2 nmol/kg of POMO was significantly
antagonized by naloxone (P < 0.05, ANOVA), but not
by naltrindole and nor-BNI (P > 0.05, ANOVA). Thus, it
appears that the activation of the MOR, but not DOR and
TABLE 3 | Antinociceptive activity and gastrointestinal transit inhibition by POMO
in mice after s.c. administration.
Antinociceptive activitya Gastrointestinal transitb
AD50 (µg/kg, s.c.) (95% CI) ED50 (µg/kg, s.c.) (95% CI)
14-OMO 53 (48–58)c 37 (35–39)
POMO 0.70 (0.63–0.77) 1.70 (0.80–3.58)
Morphine 6690 (4468–9348)c 3800 (3400–4330)
aDetermined in the hot-plate assay. Antinociceptive dose 50% with 95% confidence
intervals (AD50, 95% CI), (n = 6–8 mice per group). bDetermined in the charcoal
test. Effective dose 50% with 95% confidence intervals (ED50, 95% CI), (n = 8 mice
per group). cData from Lattanzi et al. (2005).
KOR are responsible for POMO-induced acute thermal
antinociception.
One of the most frequent adverse effects of opioid analgesics
is constipation, as a consequence of activation of opioid
receptors in the gastrointestinal tract (Imam et al., 2018).
It is well-recognized that the MOR plays a primary role
in the inhibitory control of gastrointestinal motility (Imam
et al., 2018). In vivo studies were performed with POMO
by assessing its effect on gastrointestinal transit in mice after
s.c. administration using the charcoal test (Broccardo et al.,
1998). The inhibitory effective dose, ED50 (and 95% C.I.),
was calculated and compared to 14-OMO and morphine
(Table 3). As expected, morphine effectively slowed transit
in a dose-dependent manner, with the highest tested dose
completely abolishing transit (Figure 5). Similarly, and in
agreement with our previous data in the colonic bead
expulsion test (Lattanzi et al., 2005), 14-OMO dose-dependently
inhibited gastrointestinal motility in mice, with the highest dose
producing a 90% inhibition. Although POMO also decreases
gastrointestinal transit, its actions reached only a 50% inhibition
(Figure 5).
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FIGURE 4 | Opioid receptor selectivity of POMO-induced antinociception in
the hot-plate assay in mice after s.c. administration. Antinociceptive effect of
POMO (2 nmol/kg, s.c.) measured at 20 min was antagonized by
pretreatment with naloxone (NLX, 1 mg/kg, s.c., –10 min), but not by
naltrindole (NTI, 3 mg/kg, s.c., –10 min) and nor-binaltorphimine (nor-BNI,
20 mg/kg, s.c., –24 h). ∗∗∗P < 0.001 vs. saline-pretreated group (ANOVA with
Tukey’s post hoc test). Data are shown as mean %MPE ± SEM (n = 6 mice
per group).
FIGURE 5 | POMO produces antinociception with reduced constipation after
s.c. administration in mice. Antinociception (hot-plate assay) vs.
gastrointestinal transit inhibition (charcoal test) of POMO, 14-OMO, and
morphine. (n = 6–8 mice per group).
DISCUSSION
During the past decades of opioid research, there has been
an intensive hunt for an alternative to currently available
opioids, which would produce powerful analgesia without
the harmful side effects (Bannister et al., 2017; Yekkirala
et al., 2017). In this study, we have addressed the exploration
of in vitro and in vivo pharmacological profiles of a new
opioid agonist from the class of N-methylmorphinan-6-ones,
POMO (Figure 1). The major finding is that POMO displays
potent mixed MOR/DOR/KOR agonism and extraordinarily
antinociceptive activity through MOR-mediated mechanisms
with considerably reduced propensity for constipation in mice
after s.c. administration.
Opioid drug discovery approaches have uncovered that
functionalizing position 14 in the morphinan skeleton gives rise
to opioid ligands with distinct functional profiles in vitro and
in vivo that are appraised as valuable and potential therapeutics
and important research probes (Fürst and Hosztafi, 2008; Lewis
and Husbands, 2011; Stavitskaya and Coop, 2011; Spetea and
Schmidhammer, 2012; Spetea et al., 2013). Combining in vitro
ligand binding and functional assays and in vivo behavioral
approaches, we show that the 14-O-phenylpropyl substitution
in POMO compared to the 14-O-methyl substitution in 14-
OMO has a strong influence on the interaction with opioid
receptors in terms of receptor binding and activation. The
in vitro assessment of binding affinities revealed that the
introduction of an arylalkoxy group, that is, phenylpropoxy
at position 14, maintained the high affinity at the MOR,
while markedly increasing affinities at DOR and KOR, hence
resulting in a complete loss of MOR selectivity of POMO.
These data extend our prior structure-activity relationship
(SAR) observations in terms of opioid receptor binding in
the series of N-methylmorphinan-6-ones when comparing 14-
hydroxy and 14-alkoxy analogs (Schmidhammer et al., 1984;
Lattanzi et al., 2005; Spetea et al., 2005). Similar to 14-OMO,
POMO is characterized as agonist in vitro and in vivo activity,
while exhibiting a distinct functional profile. We showed that
in vitro functional activity is largely affected by the replacement
of the 14-O-methyl group with a 14-O-phenylpropyl group
changing the MOR functionally selective 14-OMO to a potent
MOR/DOR full agonist and KOR partial agonist. Notably,
POMO exhibited increased affinity and efficacy at the MOR
compared to oxymorphone (K i = 0.97 nM and EC50 = 7.89 nM)
(Lattanzi et al., 2005; Dumitrascuta et al., 2017) and morphine
(K i = 6.55 nM and EC50 = 34.4 nM) (Ben Haddou et al., 2014),
two clinically used opioids.
Our findings from behavioral studies using a mouse model
of acute thermal nociception establish POMO as an extremely
potent opioid agonist in vivo exhibiting antinociceptive efficacy
(AD50 = 0.7 nmol/kg) after s.c. administration in mice.
Antinociceptive potency of POMO was found to be more than
70-fold higher than that of 14-OMO, and over 9000-fold when
compared to morphine. While introduction of a 14-O-methyl
group in oxymorphone, affording 14-OMO, caused an increase
up to 40-fold in antinociceptive potency (Schmidhammer
et al., 1984), the presence of the 14-phenylpropoxy group
in POMO resulted in a further substantial increase (>1400-
fold) than that reported for oxymorphone in the hot-plate
assay in mice after s.c. administration (Dumitrascuta et al.,
2017). Thus, substitution of the 14-O-methyl group in 14-
OMO with a 14-O-phenylpropyl substituent in POMO leads
to a highly potent and efficacious opioid analgesic. The
SAR observations derived in this study from the in vivo
pharmacological findings on antinociceptive properties are in
qualitative agreement with the in vitro functional activities of
targeted opioid agonists. The current findings support and extend
our observations on major alterations of the pharmacological
profile upon the introduction of a 14-O-phenylpropyl group
into the opioid antagonists naloxone and naltrexone (Greiner
et al., 2003). Hence, naloxone and naltrexone were converted
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into nonselective ligands with very high affinities at all three
opioid receptors, and potent antinociceptive agents in mice
after s.c. administration as a result of the presence of the 14-
O-phenylpropyl substituent (Greiner et al., 2003). However, in
the present work, we report on a more thorough evaluation
on the consequence of the presence of 14-O-phenylpropyl
group in N-methylmorphinan-6-ones including the mechanism
of action for analgesic effects, together with first behavioral
studies on the inhibition of gastrointestinal transit. Using
pharmacological approaches, we demonstrated that POMO-
induced antinociception is mediated through the activation
of the MOR, and it does not involve DOR and KOR, as
naltrindole and nor-BNI, respectively, did not antagonize the
acute thermal antinociceptive effect of POMO in the hot-plate
assay in mice.
Prescription opioid use has increased rapidly over the past
years (Skolnick and Volkow, 2016; Severino et al., 2018) as
have related adverse events including constipation, respiratory
depression, tolerance, and dependence (Benyamin et al., 2008;
Imam et al., 2018). Respiratory depression is of major concern to
clinicians due to its potential for producing fatal outcomes and
the primary cause of opioid-related overdose mortality (Imam
et al., 2018; Severino et al., 2018). Development of analgesic
tolerance pose challenges for compliance and is particularly
problematic in long-term chronic pain users (Benyamin et al.,
2008; Severino et al., 2018). Opioid-induced constipation is
one of the most common and most bothersome side effect of
opioid analgesics, and can significantly impact the quality of
life (Szigethy et al., 2018). The incidence of constipation is
reported in 40–95% of opioid treated patients (Imam et al.,
2018). In association with constipation, patients develop other
gastrointestinal side effects, including vomiting and nausea,
which pose major challenges for compliance and continuation of
the therapy for chronic pain management (Imam et al., 2018). All
three opioid receptors types, MOR, DOR, and KOR, are present
in the gastrointestinal tract of humans (Holzer, 2004; Galligan
and Akbarali, 2014). However, opioid-induced inhibition of
gastrointestinal transit appears to be mainly mediated by the
MOR, as MOR agonists predominantly increase gastric emptying
time and inhibit gastrointestinal motility that contributes to
nausea and vomiting (Herndon et al., 2002; Imam et al.,
2018). In this study, we report on the reduced propensity of
POMO to produce constipation at antinociceptive doses after
s.c. administration in mice. Based on the calculated ratios of
ED50(constipation) vs. AD50(antinociception) values of 0.54,
0.67, and 2.43 for morphine, 14-OMO and POMO, respectively,
it is evident that morphine and 14-OMO cause inhibition of
gastrointestinal motility at subanalgesic doses, while POMO
showed a larger therapeutic window. Notably, we established that
in the charcoal test, POMO produced fourfold less inhibition
of the gastrointestinal transit than 14-OMO and morphine in
mice.
Evaluation of pharmacokinetics (PK) is an important
aspect in drug discovery and development, specially in
understanding the behavior of bioactive molecules and
correlation with pharmacological activities (Faller, 2008).
The in silico determination of the partition coefficient (logP)
and distribution coefficient at pH 7.4 (logD7.4) of 14-OMO
and POMO was made using the software MarvinSketch 18.8
(ChemAxon). The calculated logP (clogP) values of 14-OMO
and POMO were 1.45 and 3.88, respectively, and the calculated
logD7.4 (clogD7.4) values were 0.48 and 2.89, respectively,
indicative for their good capability to enter the central nervous
system. The clogP and clogD7.4 of morphine are 1.23 and
−0.57, respectively. Based on the calculated PK parameters,
POMO showed a much higher lipophilicity than 14-OMO and
morphine, which may account for its pharmacological effects
observed in vivo.
Herein, we have shown that POMO was highly potent in
inducing acute thermal antinociception, via activation of the
MOR. In vitro, POMO is a mixed MOR/DOR full agonist, as
well as a potent KOR partial agonist. The design of ligands that
can act at multiple opioid receptors has emerged as a promising
new approach to analgesic drug development to potentially
lower side effects and to increase analgesic efficacy, especially
in chronic pain conditions (Ananthan, 2006; Kleczkowska et al.,
2013; Chan et al., 2017; Günther et al., 2017). All opioid
receptors, MOR, DOR, and KOR, are crucial modulators of both
nociception and opioid analgesia (Pasternak, 2014; Stein, 2016),
and are co-localized in nociceptive sensory neurons (Erbs et al.,
2015; Massotte, 2015). Compared to the pain relief triggered
upon MOR activation in acute pain conditions, agonism at the
DOR alone is relatively ineffective (Gavériaux-Ruff and Kieffer,
2011). However, DOR activation can be therapeutically beneficial
in the management of persistent inflammatory pain states
(Gavériaux-Ruff et al., 2008; Vanderah, 2010), with synergistic
agonism at MOR and DOR increasing the overall analgesic
effects (Fujita et al., 2015). Activation of the KOR also leads
to effective analgesia, especially in visceral pain models (Kivell
and Prisinzano, 2010; Yekkirala et al., 2017). Besides, there is
less abuse potential, fewer gastrointestinal-related complications
and reduced respiratory depression for DOR and KOR agonists
compared to MOR agonists (Benyamin et al., 2008; Pasternak
and Pan, 2013; Imam et al., 2018). Numerous biochemical and
pharmacological studies and studies with genetically modified
mice have provided evidence on the modulatory interactions
between opioid receptor types, and the existence of MOR/DOR,
DOR/KOR, and MOR/KOR heterodimers is recognized (Fujita
et al., 2015; Massotte, 2015), and nowadays targeted for the
development of bivalent ligands (Ananthan, 2006; Kleczkowska
et al., 2013; Fujita et al., 2015; Massotte, 2015; Chan et al.,
2017; Günther et al., 2017). On this basis, the activity profile
established in this study for POMO as a ligand that can
simultaneously bind and activate multiple opioid receptors is of
major relevance.
These results provide valuable insights on the SAR in the
N-methylmorphinan-6-ones class of opioids, by broadening the
current understanding of the impact of different substituents at
position 14 on ligand-receptor binding, receptor activation and
link between antinociception and side effects (i.e., constipation).
Future studies remain to analyze in more detail pathway-
dependent agonist efficacy and signaling (i.e., biased agonism),
effectiveness in models of chronic pain and other opioid
typical-side effects. Thus, position 14 in the morphinan scaffold
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represents a feasible site for tuning functional in vitro and in vivo
activities toward finding effective and safer opioid analgesics.
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